Search

everythinglearnresearchcommunity

for

Search:↓

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Hair loss itch stopped by adding RU58841 to treatment. Topical Finasteride and Pyrilutamide also mentioned as potential itch solutions.

A user is considering a hair transplant and seeks advice on choosing a clinic, mentioning Spain, Turkey, and the U.S. as options. They are inspired by FC Barcelona goalkeeper ter Stegen's results and are willing to spend up to 50k euros for the best outcome.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

Significant hair regrowth was achieved over six months using minoxidil, finasteride, microneedling, biotin and collagen shampoo, and MSM powder. The user feels more confident and may consider a hair transplant if necessary.

A dental technician claims malocclusion causes pattern hair loss due to poor scalp circulation. Users debate this, noting treatments like finasteride, minoxidil, and microneedling focus on DHT and blood flow.

A user shared their experience with hair loss treatments Minoxidil and Finasteride. They saw improvement but stopped using them, leading to significant hair loss, and are now considering restarting the treatments.

A user discusses starting nandrolone replacement therapy to stop hair loss and improve hair health, noting its benefits over finasteride. They report halted hair loss, improved skin, increased muscle, and a calm mood after three weeks.

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

After stopping finasteride, the user retained hair without noticeable balding, suggesting an unusual reaction to the medication. The user initially experienced rapid hair loss and itchiness, possibly due to male pattern baldness, but maintained hair stability after tapering off finasteride.

Stopping finasteride often leads to rapid hair loss, returning to a genetic baseline, as the drug temporarily halts hair loss and promotes regrowth. The discussion explores the complexity of hair loss, suggesting that factors beyond DHT, such as genetics and scalp conditions, may play a role.

The user had a rough week after being told they couldn't get a hair transplant due to insufficient donor area and worsening balding. They were advised to increase their oral Minoxidil dosage and consider switching from Finasteride to Dutasteride.

A 25-year-old man with hair loss from bleach damage is using oral minoxidil and considering adding Dutasteride for better regrowth and prevention. He seeks advice on Dutasteride's effectiveness and potential benefits over finasteride, and is also curious about RU58841.

User considers scalp micropigmentation (SMP) for hair loss. Mixed opinions shared; some regret it, others satisfied. Choosing reputable clinic and technician is important.

Long-term finasteride and minoxidil user shares tips for dealing with hair loss, including finding a shorter hairstyle, using finasteride, and not obsessing over hair. Users discuss washing frequency, alternative treatments, and focusing on other aspects of life.

Whether using both Fluridil and Alfatradiol together could be more effective than either one alone as a hair loss treatment, given their different mechanisms of action.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.